$ 215 million cancer immunotherapy biomarker consortium debuts

Nature Reviews Drug Discovery 16, 743 (2017). doi:10.1038/nrd.2017.223 Author: Asher Mullard The NIH and 11 biopharmaceutical companies have partnered to identify, develop and validate new biomarkers that will accelerate the development of cancer immunotherapies.Because these drugs recruit the immune system to kill tumours, conventional criteria for measuring responses to cancer therapies may not effectively capture
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research